TY - JOUR AB - For hormone receptor‑positive, HER2‑negative breast cancer patients with metastatic or advanced disease, therapy with CDK4/6 inhibitors in addition to aromatase inhibitors (AIs) or to the estrogen receptor (ER) downregulator fulvestrant has resulted in an additional therapy option and a longer progression‑free survival. In the Gynecologic‑Oncology Clinic, Diakonie‑Klinikum Schwäbisch Hall, we followed and registered our initial clinical experience with CDK4/6 inhibitors, following the side effects and tumor response over two years since they were officially approved for general use in Germany. Differences were observed when palbociclib or ribociclib was used in combination with letrozole or anastrozole or fulvestrant. The dynamic side effects and tumor response under therapy with palbociclib or ribociclib were found to be comparable with the main reported data in the official drug information. The CDK4/6 inhibitors have an important and promising role in the therapy of breast cancer patients. Patient age and therapy duration do not influence the use of palbociclib or ribociclib, although it may be important which AI is used in combination with palbociclib. AD - Clinic of Obstetrics and Gynecology, Diakonie‑Klinikum Schwäbisch Hall, D‑74523 Schwäbisch Hall, Germany Department of Medical Informatics and Biostatistics, ‘Victor Babeș’ University of Medicine and Pharmacy, Timișoara, 300041 Timișoara, Romania Clinic of Internal Medicine, Hohenloher Krankenhaus Öhringen, D‑74613 Öhringen, Germany AU - Cobec,Ionut,Marcel AU - Moleriu,Lavinia AU - Moatar,Aurica,Elisabeta AU - Rempen,Andreas DA - 2021/05/01 DO - 10.3892/etm.2021.9954 IS - 5 JO - Exp Ther Med KW - breast cancer palbociclib ribociclib CDK4/6 inhibitors side effects PY - 2021 SN - 1792-0981 1792-1015 SP - 522 ST - First clinical experience with CDK4/6 inhibitors in breast cancer therapy T2 - Experimental and Therapeutic Medicine TI - First clinical experience with CDK4/6 inhibitors in breast cancer therapy UR - https://doi.org/10.3892/etm.2021.9954 VL - 21 ER -